Simplify Logo

Full-Time

Principal Scientist

Molecular Biology

Confirmed live in the last 24 hours

Generation Bio

Generation Bio

51-200 employees

Developing genetic medicines with non-viral delivery

Hardware
Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Molecular Biology, Cell Biology, Synthetic biology, Bioengineering, Biochemistry or related discipline.
  • Minimum of 6 years of relevant experience, majority in an industry setting.
  • Experience in scientific fields of nuclear pore complex structure/ function, cellular trafficking of diverse cargos, mechanism of mRNA export, viral packaging and nuclear translocation, or related field.
  • Capacity for innovative thinking and critical problem solving.
  • Excellent communication and interpersonal skills with capacity and proven track record of working cross functionally.
Responsibilities
  • Lead design approaches for optimizing nuclear translocation of nucleic acid cargoes.
  • Generate appropriately scoped research plans to meet scientific and resourcing demands.
  • Lead execution of research individually and as part of function and cross functional teams.
  • Present scientific ideas and results effectively to different teams and groups within the organization.
  • Accountable for on-time execution of experimental projects to advance our iqDNA platform.

Generation Bio

Company Stage

IPO

Total Funding

$536.4M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-23%

2 year growth

-20%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.